RCS - Arecor Therapeutics - TETRIS PHARMA SERVICE AGREEMENT WITH SYNEOS HEALTH

Arecor TherapeuticsAnnouncement

12/12/2022 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221212:nRSL3849Ja&default-theme=true

RNS Number : 3849J  Arecor Therapeutics PLC  12 December 2022

 

 

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

 

TETRIS PHARMA SIGNS SERVICE AGREEMENT WITH SYNEOS HEALTH

 

Cambridge, UK, 12 December 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that subsidiary company, Tetris Pharma Ltd has signed a
service agreement with Syneos Health® (Nasdaq: SYNH), the only fully
integrated biopharmaceutical solutions organization purpose-built to
accelerate customer success, to support the build out of Tetris Pharma's
commercial platform across Europe.

 

See full Tetris Pharma announcement below:

 

Tetris Pharma signs service agreement with Syneos Health

 

Partnership to support Tetris Pharma roll-out of Ogluo® across Europe

 

 

12 December 2022 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a
subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC),
today announces that it has signed a service agreement with Syneos Health®
(Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions
organization purpose-built to accelerate customer success, to support the
build out of Tetris Pharma's commercial platform across Europe.

 

Through this partnership, Syneos Health will provide commercial support
through an outsourced contract sales services to accelerate healthcare
practitioner awareness of Tetris Pharma's flagship product, Ogluo®, for
people living with diabetes across initial launch territories.

 

Dr. Shafiq Choudhary, Managing Director, Tetris Pharma, commented:

 

"Following the recent launch of Ogluo® (glucagon prefilled autoinjector pen)
in Germany, we are focused on continuing its accelerated roll-out across
Europe. Syneos Health was one of several potential partners that were
evaluated during the process of partnering with an organisation that would
provide a multitude of commercial options to help establish the product across
Europe. Partnering with Syneos Health, a leader in clinical research, medical
affairs, and commercialisation services for the pharmaceutical industry, is
key to building our reputation as specialists in the marketing, sales, and
distribution of commercial-stage specialty hospital products across the UK and
Europe."

 

Enquiries:

 

Tetris Pharma

Shafiq Choudhary            +44 (0)1628 337579

 

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage
specialty pharmaceutical company with expertise in registering, marketing,
sales and the distribution of speciality hospital products across the UK and
Europe. Our experienced team has a proven history of building and growing
sales. Having secured distribution rights for already licensed products across
Europe, we have a portfolio of niche injectable products including Ogluo(®),
a ready-to-use glucagon for emergency use to treat hypoglycaemia. Ogluo
prescribing information can be found here
(https://www.medicines.org.uk/emc/search?q=ogluo) . We collaborate with
partners to provide patients with effective treatments and quality healthcare
by ensuring we deliver accountability, partnership and performance.

 

For further information, please visit tetrispharma.com
(http://tetrispharma.com)

 

 

-ENDS-

 

 

For more information, please contact:

 

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700

 Chris Gardner, David Daley, Angela Gray          Email: arecor@consilium-comms.com

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATTBMTMTMBBMT